Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 28;13(9):219.
doi: 10.3390/ph13090219.

Towards Better Delivery of Cannabidiol (CBD)

Sophie Anne Millar  1 , Ryan Francis Maguire  2 , Andrew Stephen Yates  1 , Saoirse Elizabeth O'Sullivan  1
Affiliations
Review

Towards Better Delivery of Cannabidiol (CBD)

Sophie Anne Millar et al. Pharmaceuticals (Basel). .

Abstract

Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of the drug substance also limits the likelihood of an expensive, full development programme in anything other than orphan indications. Potential avenues to overcome these issues with CBD include self-emulsifying drug delivery systems, improved crystal formulations and other solid-state delivery formulations, which are mostly in the pre-clinical or early clinical stages of development. This review identifies issues compromising current delivery of solid-state CBD, and how advanced pharmaceutical development strategies can enable CBD to realise the full potential as a successful therapeutic agent.

Keywords: CBD; cannabidiol; clinical development; formulation.

PubMed Disclaimer

Conflict of interest statement

S.E.O., S.A.M. and A.S.Y. are independent consultants and work as paid scientific advisors to Artelo Biosciences.

References

    1. Mitelpunkt A., Kramer U., Hausman Kedem M., Zilbershot Fink E., Orbach R., Chernuha V., Fattal-Valevski A., Deutsch L., Heffetz D., Sacks H. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy Behav. 2019;98:233–237. doi: 10.1016/j.yebeh.2019.07.007. - DOI - PubMed
    1. Devinsky O., Patel A.D., Cross J.H., Villanueva V., Wirrell E.C., Privitera M., Greenwood S.M., Roberts C., Checketts D., VanLandingham K.E., et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N. Engl. J. Med. 2018;378:1888–1897. doi: 10.1056/NEJMoa1714631. - DOI - PubMed
    1. Devinsky O., Marsh E., Friedman D., Thiele E., Laux L., Sullivan J., Miller I., Flamini R., Wilfong A., Filloux F., et al. Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial. Lancet Neurol. 2016;15:270–278. doi: 10.1016/S1474-4422(15)00379-8. - DOI - PubMed
    1. Thiele E.A., Marsh E.D., French J.A., Mazurkiewicz-Beldzinska M., Benbadis S.R., Joshi C., Lyons P.D., Taylor A., Roberts C., Sommerville K., et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–1096. doi: 10.1016/S0140-6736(18)30136-3. - DOI - PubMed
    1. Hess E.J., Moody K.A., Geffrey A.L., Pollack S.F., Skirvin L.A., Bruno P.L., Paolini J.L., Thiele E.A. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617–1624. doi: 10.1111/epi.13499. - DOI - PubMed

Grants and funding

LinkOut - more resources